A citation-based method for searching scientific literature

Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris, Lorraine A Fitzpatrick, Felicia Cosman, Claus Christiansen. JAMA 2016
Times Cited: 364







List of co-cited articles
1022 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi,[...]. N Engl J Med 2016
630
52

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer. N Engl J Med 2017
468
50

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
R M Neer, C D Arnaud, J R Zanchetta, R Prince, G A Gaich, J Y Reginster, A B Hodsman, E F Eriksen, S Ish-Shalom, H K Genant,[...]. N Engl J Med 2001
46

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Steven R Cummings, Javier San Martin, Michael R McClung, Ethel S Siris, Richard Eastell, Ian R Reid, Pierre Delmas, Holly B Zoog, Matt Austin, Andrea Wang,[...]. N Engl J Med 2009
34

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer,[...]. Lancet 2018
197
31

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli,[...]. J Clin Endocrinol Metab 2018
73
35

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
Gary Hattersley, Thomas Dean, Braden A Corbin, Hila Bahar, Thomas J Gardella. Endocrinology 2016
137
26

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Dennis M Black, Pierre D Delmas, Richard Eastell, Ian R Reid, Steven Boonen, Jane A Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man,[...]. N Engl J Med 2007
25

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant,[...]. Lancet 2017
171
19

Romosozumab in postmenopausal women with low bone mineral density.
Michael R McClung, Andreas Grauer, Steven Boonen, Michael A Bolognese, Jacques P Brown, Adolfo Diez-Perez, Bente L Langdahl, Jean-Yves Reginster, Jose R Zanchetta, Scott M Wasserman,[...]. N Engl J Med 2014
677
18

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Paul M Wallace, Hang Lee, Robert M Neer, Sherri-Ann M Burnett-Bowie. Lancet 2015
236
17

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
D M Black, S R Cummings, D B Karpf, J A Cauley, D E Thompson, M C Nevitt, D C Bauer, H K Genant, W L Haskell, R Marcus,[...]. Lancet 1996
17

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
B Ettinger, D M Black, B H Mitlak, R K Knickerbocker, T Nickelsen, H K Genant, C Christiansen, P D Delmas, J R Zanchetta, J Stakkestad,[...]. JAMA 1999
16

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Richard Eastell, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Dolores Shoback. J Clin Endocrinol Metab 2019
215
15

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta,[...]. J Bone Miner Res 2018
85
17

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Henry G Bone, Rachel B Wagman, Maria L Brandi, Jacques P Brown, Roland Chapurlat, Steven R Cummings, Edward Czerwiński, Astrid Fahrleitner-Pammer, David L Kendler, Kurt Lippuner,[...]. Lancet Diabetes Endocrinol 2017
337
15

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Ivo Valter, Lorraine A Fitzpatrick, Bente Juel Riis, Claus Christiansen, John P Bilezikian,[...]. Mayo Clin Proc 2017
70
20

Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Ian R Reid, Anne M Horne, Borislav Mihov, Angela Stewart, Elizabeth Garratt, Sumwai Wong, Katy R Wiessing, Mark J Bolland, Sonja Bastin, Gregory D Gamble. N Engl J Med 2018
149
14

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Felicia Cosman, Erik Fink Eriksen, Chris Recknor, Paul D Miller, Núria Guañabens, Christian Kasperk, Philemon Papanastasiou, Aimee Readie, Hanumantha Rao, Jürg A Gasser,[...]. J Bone Miner Res 2011
210
13

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
S R Cummings, D M Black, D E Thompson, W B Applegate, E Barrett-Connor, T A Musliner, L Palermo, R Prineas, S M Rubin, J C Scott,[...]. JAMA 1998
13

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Kenneth G Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W Donley, Kathleen A Taylor, Gail P Dalsky, Robert Marcus. N Engl J Med 2007
533
13

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
E Michael Lewiecki, Rajani V Dinavahi, Marise Lazaretti-Castro, Peter R Ebeling, Jonathan D Adachi, Akimitsu Miyauchi, Evelien Gielen, Cassandra E Milmont, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2019
64
20


Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Felicia Cosman, Jeri W Nieves, David W Dempster. J Bone Miner Res 2017
105
13

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Charles H Chesnut, Arne Skag, Claus Christiansen, Robert Recker, Jacob A Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C Schimmer,[...]. J Bone Miner Res 2004
770
13

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Dennis M Black, Ann V Schwartz, Kristine E Ensrud, Jane A Cauley, Silvina Levis, Sara A Quandt, Suzanne Satterfield, Robert B Wallace, Douglas C Bauer, Lisa Palermo,[...]. JAMA 2006
904
13

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.
Dolores Shoback, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Richard Eastell. J Clin Endocrinol Metab 2020
73
17

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Benjamin Z Leder, Louis St L O'Dea, José R Zanchetta, Prasana Kumar, Kathleen Banks, Kathleen McKay, C Richard Lyttle, Gary Hattersley. J Clin Endocrinol Metab 2015
132
12


Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
J A Kanis, N C Harvey, E McCloskey, O Bruyère, N Veronese, M Lorentzon, C Cooper, R Rizzoli, G Adib, N Al-Daghri,[...]. Osteoporos Int 2020
86
13

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Pascale Chavassieux, Roland Chapurlat, Nathalie Portero-Muzy, Jean-Paul Roux, Pedro Garcia, Jacques P Brown, Cesar Libanati, Rogely W Boyce, Andrea Wang, Andreas Grauer. J Bone Miner Res 2019
44
27

Clinician's Guide to Prevention and Treatment of Osteoporosis.
F Cosman, S J de Beur, M S LeBoff, E M Lewiecki, B Tanner, S Randall, R Lindsay. Osteoporos Int 2014
11

Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.
S Ferrari, C Libanati, Celia Jow Fang Lin, J P Brown, F Cosman, E Czerwiński, L H de Gregόrio, J Malouf-Sierra, J-Y Reginster, A Wang,[...]. J Bone Miner Res 2019
42
26

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.
Mary L Bouxsein, Richard Eastell, Li-Yung Lui, Lucy A Wu, Anne E de Papp, Andreas Grauer, Fernando Marin, Jane A Cauley, Douglas C Bauer, Dennis M Black. J Bone Miner Res 2019
85
12

Zoledronic acid and clinical fractures and mortality after hip fracture.
Kenneth W Lyles, Cathleen S Colón-Emeric, Jay S Magaziner, Jonathan D Adachi, Carl F Pieper, Carlos Mautalen, Lars Hyldstrup, Chris Recknor, Lars Nordsletten, Kathy A Moore,[...]. N Engl J Med 2007
11

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
J Reginster, H W Minne, O H Sorensen, M Hooper, C Roux, M L Brandi, B Lund, D Ethgen, S Pack, I Roumagnac,[...]. Osteoporos Int 2000
11

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner, Paul D Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, Stephane Horlait. J Clin Endocrinol Metab 2018
93
11

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Joy N Tsai, Alexander V Uihlein, Hang Lee, Ruchit Kumbhani, Erica Siwila-Sackman, Elizabeth A McKay, Sherri-Ann M Burnett-Bowie, Robert M Neer, Benjamin Z Leder. Lancet 2013
252
10

Mechanisms of anabolic therapies for osteoporosis.
Ernesto Canalis, Andrea Giustina, John P Bilezikian. N Engl J Med 2007
434
10

Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
Felicia Cosman, Gary Hattersley, Ming-Yi Hu, Gregory C Williams, Lorraine A Fitzpatrick, Dennis M Black. J Bone Miner Res 2017
51
19

Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy,[...]. J Clin Endocrinol Metab 2019
84
11

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, Yuli Zhu, Katelyn Foley, Hang Lee, Robert M Neer. J Clin Endocrinol Metab 2014
154
9

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
P Hadji, J R Zanchetta, L Russo, C P Recknor, K G Saag, F E McKiernan, S L Silverman, J Alam, R T Burge, J H Krege,[...]. Osteoporos Int 2012
70
12

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Steven R Cummings, Serge Ferrari, Richard Eastell, Nigel Gilchrist, Jens-Erik Beck Jensen, Michael McClung, Christian Roux, Ove Törring, Ivo Valter, Andrea T Wang,[...]. J Bone Miner Res 2018
273
9

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
John P Bilezikian, Gary Hattersley, Bruce H Mitlak, Ming-Yi Hu, Lorraine A Fitzpatrick, Christine Dabrowski, Paul D Miller, Socrates E Papapoulos. Curr Med Res Opin 2019
13
69

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
Pauline M Camacho, Steven M Petak, Neil Binkley, Dima L Diab, Leslie S Eldeiry, Azeez Farooki, Steven T Harris, Daniel L Hurley, Jennifer Kelly, E Michael Lewiecki,[...]. Endocr Pract 2020
114
9

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
U A Liberman, S R Weiss, J Bröll, H W Minne, H Quan, N H Bell, J Rodriguez-Portales, R W Downs, J Dequeker, M Favus. N Engl J Med 1995
9

T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
Felicia Cosman, E Michael Lewiecki, Peter R Ebeling, Eric Hesse, Nicola Napoli, Toshio Matsumoto, Daria B Crittenden, Maria Rojeski, Wenjing Yang, Cesar Libanati,[...]. J Bone Miner Res 2020
15
60

PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.
Ross W Cheloha, Samuel H Gellman, Jean-Pierre Vilardaga, Thomas J Gardella. Nat Rev Endocrinol 2015
103
8

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Jacques E Rossouw, Garnet L Anderson, Ross L Prentice, Andrea Z LaCroix, Charles Kooperberg, Marcia L Stefanick, Rebecca D Jackson, Shirley A A Beresford, Barbara V Howard, Karen C Johnson,[...]. JAMA 2002
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.